Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population
Open Access
- 1 January 2010
- journal article
- research article
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 58 (2) , 125-30
Abstract
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients and assess the ocular side-effects of iron chelating agents. Materials and Methods: In this prospective observational study, 45 multiple transfused beta-thalassemia major children between six months and 21 years of age were enrolled and assigned groups according to the treatment regimens suggested. Group A received only blood transfusions, Group B blood transfusions with subcutaneous desferrioxamine, Group C blood transfusions with desferrioxamine and oral deferriprone and Group D blood transfusions with deferriprone. Ocular status at the time of enrolment was documented. Subjects were observed quarterly for one year for changes in ocular status arising due to the disease process and due to iron chelation therapy. Children with hemoglobinopathies other than beta-thalassemia major, congenital ocular anomalies and anemia due to other causes were excluded. Results: Ocular involvement was observed in 58% of patients. Lenticular opacities were the most common ocular finding (44%), followed by decreased visual acuity (33%). An increased occurrence of ocular changes was observed with increase of serum ferritin and serum iron levels as well as with higher number of blood transfusions received. Desferrioxamine seemed to have a protective influence on retinal pigment epithelium (RPE) mottling. Occurrence of lenticular opacities and RPE degeneration correlated positively with use of desferrioxamine and deferriprone respectively. Follow-up of patients for one year did not reveal any change in ocular status. Conclusion: Regular ocular examinations can aid in preventing, delaying or ameliorating the ocular complications of thalassemia.Keywords
This publication has 10 references indexed in Scilit:
- Ocular Findings Among Thalassemia PatientsAmerican Journal of Ophthalmology, 2006
- Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicityAmerican Journal of Hematology, 2003
- Ocular Abnormalities in Patients with β ThalassemiaAmerican Journal of Ophthalmology, 1989
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Desferroxamine and ocular toxicity, causal or concomitant relationship.1986
- Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.1985
- Ocular changes in patients undergoing long-term desferrioxamine treatment.British Journal of Ophthalmology, 1984
- Deferoxamine (Desferal®)-induced Toxic Retinal Pigmentary Degeneration and Presumed Optic NeuropathyOphthalmology, 1984
- OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINEThe Lancet, 1983
- Lens Opacities in ThalassemiaJournal of Pediatric Ophthalmology & Strabismus, 1978